Rayvio_News_Filter
$SLXN 🏥
Silexion Therapeutics announced the first patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, advancing SIL204 into active patient treatment.
Curated for market relevance
